phase – Communicable Diseases Research

Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Article

Published on 2022-12-012022-11-15
Journal: Emerging Microbes & Infections
[Category] COVID19(2023년), SARS, 변종, 비임상, 진단, 치료기술, 치료제,

Treatment Strategies and Perforation Rate of Acute Appendicitis During the Early Phase of the Covid-19 Pandemic: A Swedish Cohort Study

Research article

Published on 2022-12-012022-10-05
Journal: The Journal of surgical research
[Category] 치료법,

Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial

Article

Published on 2022-11-082022-11-16
Journal: Trials
[Category] SARS, 변종,

[키워드] adaptive anti-COVID-19 IVIG antivirals clinical evidence clinical trial collected convalescent convalescent plasma COVID-19 cumulative death Efficacy eligibility criteria evaluate Health hyperimmune immunization immunomodulators intravenous Intravenous immunoglobulin low dose monoclonal antibodies Neutralizing non-specific novel Novel coronavirus outcome Passive passive immunization Patient phase Pneumonia polyclonal polyclonal antibodies Pooled convalescent plasma Potential treatment Randomized Randomized controlled trial receive Recovered COVID-19 patients reported SARS CoV-2 SARS CoV-2. SARS-CoV-2 sealed Secondary outcomes severe COVID-19 severe COVID-19 patient severe COVID-19 patients Standard of care Steroids Study protocol therapeutic option therapy treat Treatment Trial variant variants of concern virus virus particles World Health Organization
[DOI] 10.1186/s13063-022-06860-2 PMC 바로가기

A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part

Article

Published on 2022-10-182022-11-15
Journal: Antimicrobial Agents and Chemotherapy
[Category] COVID19(2023년), SARS, 치료제,

[키워드] acute respiratory syndrome All adverse event Asymptomatic baseline clinical coronavirus coronavirus disease COVID-19 Culture demonstrated double-blind Efficacy and safety ensitrelvir fumaric acid greater group groups intention-to-treat population Japan Japanese log median time Mild Mild-to-moderate moderate multicenter novel oral Part Patient phase phase 2/3 Placebo positive Primary outcome proof-of-concept study protease Protease inhibitor Randomized receive reduced registry Result S-217622 SARS-CoV-2 SARS-CoV-2 3C-like protease inhibitor SARS-CoV-2 clearance SARS-COV-2 infection SARS-CoV-2 RNA SARS-CoV-2 viral the SARS-CoV-2 tissue Treatment viral clearance Viral RNA viral titer viral titer.
[DOI] 10.1128/aac.00697-22 PMC 바로가기

A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network

Article

Published on 2022-10-082022-11-15
Journal: Trials
[Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] ≥75 years. adaptive addition advanced age age Analysis Antibody titre benefit BNT162b2 BNT162b2 (Comirnaty®) booster booster dose changes in Clinical course collected concern conducted COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine dose Endpoint enzyme-linked immunosorbent evaluate exploratory fourth dose humoral immune response immunosenescence include individual initial Intervention mRNA-1273 mRNA-1273 (Spikevax®) multicentre neutralising neutralising antibody titre Older Part Patient performed phase phase II primary endpoint protocol qPCR Quantitative randomisation randomised randomised controlled reactogenicity Research risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine secondary subgroup T cell response the primary endpoint Trial triggered vaccination Vaccine vaccine-induced immune response variants variants of concern VoC wild-type wild-type virus
[DOI] 10.1186/s13063-022-06791-y PMC 바로가기

Wellbeing and coping of UK nurses, midwives and allied health professionals during COVID-19-a cross-sectional study

Article

Published on 2022-09-212022-11-16
Journal: PLoS ONE
[Category] SARS, 변종,

A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects

Article

Published on 2022-09-132022-11-16
Journal: Frontiers in Immunology
[Category] SARS, 변종,

[키워드] Administered Adults age antigenic approved booster children clinical development comparable country CoV COVID-19 pandemic COVID-19 severity disease Effectiveness Efficacy Emergency use Emergency use authorization generate geometric mean titer group Healthcare system Heterologous heterologous prime and boost vaccines heterologous prime-boost immune response inactivated Inactivated vaccine inactivated virus adjuvanted vaccine increase in India induce Like memory B morbidity Mortality neutralization neutralization titer original antigenic sin over pandemic pediatric phase Population prime and boost reactogenicity reduce reduction in robust safety profile SARS – CoV – 2 SARS-CoV-2 variant seroconversion rate symptomatic COVID-19 disease synergy T-cell responses TLR7/8 vaccinated individuals vaccination Vaccine vaccine challenges Vaccine development vaccine dose Vaccines variants of concern variants of concern (VOCs). virus VOCs waning immunity
[DOI] 10.3389/fimmu.2022.940715 PMC 바로가기

Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations

Article

Published on 2022-09-012022-11-15
Journal: Clinical microbiology and infection : the official
[Category] COVID19(2023년), SARS, 진단,

[키워드] Advax-CpG adverse event antibody Cellular immune response composed conducted COVID-19 COVID-19 vaccine dose double-blind fatigue geometric mean concentration humoral incidence injection site pain Mild outcome participant phase Phase 2 phase 2 trial Placebo placebo-controlled Population primary immunogenicity Protein Randomized randomized placebo-controlled trial receive Safety safety profile SARS-CoV-2 SARS-CoV-2 spike protein second dose Serious Adverse Event Seroconversion seroconversion rate seronegative seropositive SpikoGen subunit subunit protein vaccine. the placebo group vaccination Vaccine Volunteer were recorded
[DOI] 10.1016/j.cmi.2022.04.004 PMC 바로가기

Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial

Article

Published on 2022-09-012022-11-15
Journal: Annals of internal medicine
[Category] COVID19(2023년), SARS, 진단,

Debulking different Corona (SARS-CoV-2 delta, omicron, OC43) and Influenza (H1N1, H3N2) virus strains by plant viral trap proteins in chewing gums to decrease infection and transmission

Article

Published on 2022-09-012022-11-15
Journal: Biomaterials
[Category] COVID19(2023년), SARS, 신종인플루엔자, 치료기술,